Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more

With a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion push was just getting started. He wasn’t kidding.

The manufacturer’s parent company Samsung Group is investing an eye-popping 240 trillion won ($205 billion) through 2023 across its biopharmaceutical, semiconductor and telecommunications businesses, among others, the company said in an emailed statement.